180 Wealth Advisors LLC Grows Stock Holdings in Abrdn Life Sciences Investors (NYSE:HQL)

180 Wealth Advisors LLC lifted its stake in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 7.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 132,549 shares of the company’s stock after purchasing an additional 9,554 shares during the period. 180 Wealth Advisors LLC owned 0.51% of Abrdn Life Sciences Investors worth $1,807,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HQL. Future Financial Wealth Managment LLC acquired a new position in Abrdn Life Sciences Investors during the first quarter worth $27,000. Matisse Capital purchased a new stake in shares of Abrdn Life Sciences Investors in the fourth quarter valued at about $135,000. Blue Bell Private Wealth Management LLC increased its position in Abrdn Life Sciences Investors by 60.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock worth $136,000 after purchasing an additional 3,811 shares during the last quarter. International Assets Investment Management LLC increased its position in Abrdn Life Sciences Investors by 3,424.5% during the fourth quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock worth $149,000 after purchasing an additional 10,753 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new position in Abrdn Life Sciences Investors during the fourth quarter worth about $150,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. purchased 13,812 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were acquired at an average price of $14.08 per share, with a total value of $194,472.96. Following the purchase, the insider now directly owns 3,429,891 shares in the company, valued at approximately $48,292,865.28. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders acquired a total of 461,813 shares of company stock valued at $6,161,642 over the last quarter. 10.06% of the stock is owned by insiders.

Abrdn Life Sciences Investors Stock Performance

Shares of Abrdn Life Sciences Investors stock traded down $0.01 during mid-day trading on Friday, hitting $14.16. The stock had a trading volume of 28,060 shares, compared to its average volume of 97,110. The firm has a 50-day moving average of $13.63 and a two-hundred day moving average of $13.63. Abrdn Life Sciences Investors has a 12-month low of $11.34 and a 12-month high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Thursday, May 23rd will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 13.56%. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.39. The ex-dividend date is Wednesday, May 22nd.

Abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.